

Development of Haemophilia Treatment in the Eastern Part of Germany over the Last Decade in the Kompetenznetz Hämorrhagische Diathese Ost (KHDO)

Entwicklung der Hämophiliebehandlung im Osten Deutschlands in den letzten 10 Jahren – eine Untersuchung des Kompetenznetz Hämorrhagische Diathese Ost (KHDO)

Rebecca Mahn¹ Kristina Schilling² Robert Klamroth³ Karim Kentouche⁴ Volker Aumann⁵
 Lars Fischer⁶ Susanne Holzhauser⁷ Harry Sirb⁸ Ute Scholz⁹ Karolin Trautmann¹⁰
 Ines Halm-Heinrich¹¹ Beate Krammer-Steiner¹² Jürgen Koscielny¹³ Ute Kreibich¹⁴
 Antje Pietrzak-Büttner¹⁵ Matthias Tregel¹⁶ Ralf Knöfler¹⁷ Christian Pfrepper¹
 and the Kompetenznetzwerk Hämorrhagische Diathese Ost

¹Medical Department I, Division of Haemostaseology, University Hospital Leipzig, Leipzig, Germany

²Division of Haematology and Oncology, University Hospital Jena, Jena, Germany

³Vivantes Hospital in Friedrichshain, Berlin, Germany

⁴Department of Paediatrics, University Hospital Jena, Jena, Germany

⁵Department of Paediatrics, University Hospital Magdeburg, Magdeburg, Germany

⁶Department of Paediatrics, University Hospital Leipzig, Leipzig, Germany

⁷Department of Paediatric Haematology and Oncology, Charité University Medicine, Berlin, Germany

⁸Department of Paediatrics, DRK Hospital Lichtenstein, Lichtenstein, Germany

⁹Centre of Coagulation Disorders, Leipzig, Germany

¹⁰Department of Haematology and Oncology, University Hospital Dresden, Dresden, Germany

¹¹Department of Transfusion Medicine, University Hospital Magdeburg, Magdeburg, Germany

Address for correspondence Christian Pfrepper, Medical Department I, Division of Haemostaseology, University Hospital Leipzig, Liebigstr. 20, 04103 Leipzig, Germany (e-mail: christian.pfrepper@medizin.uni-leipzig.de).

¹²Department of Haematology and Oncology, Rostock South City Medical Centre, Rostock, Germany

¹³Haemophilia Centre (EHCCC) with outpatient ambulance in the ambulance service (AGZ) of the Charité, Charité Universitätsmedizin Berlin, Germany

¹⁴Haemophilia Ambulance, Heinrich Braun Hospital, Zwickau, Germany

¹⁵Paediatric Clinic, SRH Hospital Suhl, Suhl, Germany

¹⁶Ruppin General Hospital, Institute of Laboratory Medicine, Brandenburg Medical School, Neuruppin, Germany

¹⁷Department of Paediatric Haematology and Oncology, University Hospital Dresden, Dresden, Germany

Hämostaseologie 2020;40:119–127.

Abstract

Keywords

- ▶ haemophilia
- ▶ epidemiologic data
- ▶ factor consumption
- ▶ hepatitis C

Introduction In 2005 the Kompetenznetz Hämorrhagische Diathese Ost published epidemiologic data about patients with haemophilia A (HA) and haemophilia B (HB) in the eastern part of Germany. This study provides data about the development of treatment in these patients over the past 10 years.

Methods Data from 12 haemophilia centres in eastern Germany were retrospectively collected for the year 2015 from patients' records.

Remark: Our study includes data of 42 patients that were included in the publication by Olivieri et al, *Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany*. *Hamostaseologie* 2019. doi10.1055/s-0039-1677874.

received

March 8, 2019

accepted after revision

September 26, 2019

© 2020 Georg Thieme Verlag KG
 Stuttgart · New York

DOI <https://doi.org/10.1055/s-0039-3399493>.
 ISSN 0720-9355.

Results We evaluated 413 patients (115 children, 298 adults) with HA or HB. A total of 286 patients (69.2%) had severe haemophilia (patients with severe haemophilia, PWSH). Compared with 2005, the proportion PWSH on prophylaxis increased from 90% to 98.8% in children and from 64% to 80.2% in adults. The use of plasma-derived factor concentrates decreased from >70% to 55.3% in children and to 55.1% in adults. Mean annual factor consumption in PWSH without inhibitor was higher in 2015 compared with 2005 (children with HA: 151,489 vs. 98,894; adults with HA: 217,151 vs. 151,394; children with HB: 105,200 vs. 64,256; adults with HB: 159,185 vs. 85,295). Median annualized bleeding (annualized bleeding rate, ABR) and joint bleeding rates (annualized joint bleeding rate, AJBR) in 2015 were 2 and 0 in children and 3 and 0 in adults, respectively. In 2015 only one child (1.2%) but 101 (53.2%) adults with severe haemophilia were anti-hepatitis C virus (anti-HCV) positive. The rate of anti-HCV positive patients with active hepatitis C dropped from 63.8% to 12.9%.

Conclusions Within the last decade more patients with severe haemophilia were switched to a prophylactic regimen going along with a moderate increase in factor consumption achieving a low ABR and AJBR.

Zusammenfassung

Einleitung Im Jahr 2005 hat das Kompetenznetz Häorrhagische Diathese Ost epidemiologische Daten über Patienten im Osten Deutschlands mit Hämophilie A (HA) und B (HB) publiziert. Diese Studie liefert Daten über die Entwicklung der Hämophiliebehandlung bei diesen Patienten in den letzten 10 Jahren.

Methoden Daten von 12 Hämophiliezentren im Osten Deutschlands aus dem Jahr 2015 wurden retrospektiv aus den Patientenakten ausgewertet.

Ergebnisse Wir untersuchten 413 Patienten (115 Kinder, 298 Erwachsene) mit HA oder HB. 286 Patienten (69,2%) hatten eine schwere Hämophilie (PMSH). Im Vergleich zu 2005 ist der Anteil der PMSH mit Prophylaxe bei den Kindern von 90% auf 98,8% und bei den Erwachsenen von 64% auf 80,2% angestiegen. Der Verbrauch von plasmatischen Faktorenkonzentraten ist von >70% auf 55,3% bei Kindern und 55,1% bei Erwachsenen gesunken. Der mittlere Faktorenverbrauch bei PMSH ohne Hemmkörper war 2015 höher als 2005 (Kinder mit HA 151.489 versus 98.894, Erwachsene mit HA 217.151 versus 151.394, Kinder mit HB 105.200 versus 64.256, Erwachsenen mit HB 159.185 versus 85.295). Die mediane jährliche Blutungsrate und Gelenkblutungsrate in 2015 war 2 bzw. 0 bei Kindern und 3 bzw. 0 bei Erwachsenen. Im Jahr 2015 war lediglich ein Kind (1,2%) aber 101 (53,2%) Erwachsene mit schwerer Hämophilie anti-HCV positiv. Der Anteil der anti-HCV-positiven Erwachsenen mit aktiver Hepatitis C fiel von 63,8% auf 12,9%.

Zusammenfassung In den letzten 10 Jahren wurden mehr Patienten auf eine prophylaktische Behandlung umgestellt. Dies geht mit einem moderaten Anstieg des Verbrauchs an Faktorenkonzentraten einher, resultiert aber in einer niedrigen Blutungsrate.

Schlüsselwörter

- ▶ Hämophilie
- ▶ Epidemiologie
- ▶ Faktorenverbrauch
- ▶ Hepatitis C

Introduction

Haemophilia A and B (HA and HB) are rare hereditary bleeding disorders characterized by the deficiency or complete absence of clotting factor VIII (FVIII) or IX (FIX) leading to spontaneous bleeds into muscles and joints. The severity of the disease is determined by the residual factor activity,¹ but the clinical manifestation may vary.² For patients with severe haemophilia (PWSHs), standard of care is prophylac-

tic substitution of factor concentrates as prophylaxis reduces joint bleedings and improves joint status.³⁻⁵ Besides this, it is known that in children early prophylaxis results in a better joint status.⁶ In addition, patients still benefit from prophylaxis when it is started later in life,⁵ making prophylaxis the standard of care in all PWSHs. There are two approaches of prophylaxis with a fixed regimen depending on body weight (BW) and tailored regimens taking into account bleeding phenotype and pharmacokinetic properties.

As prophylaxis is nowadays considered standard of care in haemophilia treatment, changes in treatment strategies and factor consumption over time are of special interest.

In Germany, the annual factor consumption of patients with haemophilia (PWHs) is usually reported to the Paul Ehrlich Institute as a collective report. Some clinicians also report individual data to the German Haemophilia Registry, but in 2015 only in 38.6% of all PWSHs individual data were announced.⁷ As a result there is a lack of comprehensive data reflecting changes in factor consumption and different treatment strategies in Germany over time.

The Kompetenznetzwerk Hämorrhagische Diathese Ost (KHDO) is an association of clinicians dedicated to “supporting clinical and scientific research in the field of haemophilia and severe coagulation disorders and improving clinical care for these patients” in the eastern part of Germany. The KHDO published epidemiologic data based on the reports submitted to the Paul Ehrlich Institute regarding treatment strategies, factor consumption and infections in PWHs in eastern Germany in 2005.⁸

The aim of this study was to collect current epidemiologic data including patient characteristics, bleeding rates, weight classification and infectious diseases. Comparing these data with our previously published data from 2005, we intended to document changes in haemophilia treatment over the last decade in eastern Germany.

Methods

Retrospective data of the year 2015 from patients with HA and HB were provided from 12 haemophilia centres in eastern Germany. Data were collected from patient diaries and medical records regarding age, height, BW, blood group, dosing regimen, factor consumption, documented bleeds and inhibitory antibodies. Severity of haemophilia, bleeding events and inhibitor status were documented according to the current International Society of Thrombosis and Haemostasis (ISTH) guideline.⁹ All patients with HA or HB who had a complete patient diary for 2015 with documented bleeds and factor consumption were eligible. In addition, we included three patients with available data on virology but without completed patient diary. Data were analysed in the haemophilia centres and the treating physicians were consulted for clarification in case of conspicuities.

Bleeds were measured as documented by the patients and treating physicians. As annualized bleeding rate (ABR) all documented bleeds were summarized, while the annualized joint bleeding rate (AJBR) only refers to documented joint bleeds. In addition, major bleedings were defined as non-joint bleedings that were life-threatening or led to hospital admission or required transfusion of red blood cells. As minor bleedings all other haemorrhages with documented bleeding sites were counted. Additional substitutions without further information in patient diaries or medical records and bleedings without specified bleeding site were counted as unclear substitutions and summarized as bleedings in the total ABR.

In addition, results from human immunodeficiency virus (HIV) antibodies, anti-HBs, HB-antigen, anti-hepatitis C virus

(anti-HCV) and HCV-polymerised chain reaction (PCR) measurements were obtained in patients with available data.

Body mass index (BMI) was calculated using the formula: $BMI = \text{weight [kg]} / \text{size [m}^2\text{]} = [\text{kg/m}^2]$. For adults (≥ 18 years), BMI was classified according to the World Health Organization guideline. Overweight is therefore defined as BMI of 25 to 29 kg/m^2 and obesity as a BMI of $\geq 30 \text{ kg/m}^2$.¹⁰ In children (< 18 years), the percentile curves according to Kromeyer-Hauschild were used for classification. Overweight is here referred to as BMI between 90th and 97th percentiles, obesity between 97th and 99.5th percentiles and extreme obesity as ≥ 99.5 th percentiles.^{11,12}

For the calculation of factor consumption, 5 patients (2 children, 3 adults) with inhibitory FVIII or FIX antibodies and 2 patients (1 child, 1 adult) with a negative Bethesda test but a remaining shortened half-life after immune tolerance induction were excluded.

Statistics

For statistical analysis, values were calculated for normal distribution using the method of Shapiro–Wilk and Kolmogorov–Smirnov. As values were not normally distributed, statistical significance was determined by applying the Mann–Whitney U test. A p -value < 0.05 was rated as statistically significant. Data from 2015 were given as mean when they were compared with 2005 because data from 2005 were only available as mean. Other data from 2015 are given as median with an interquartile range (IQR; 25th and 75th percentiles). Statistical analysis was performed using SPSS version 22.

This study reports data of 42 patients that were included in the publication by Olivieri et al..¹³

Results

We screened 417 patients and excluded four patients due to inconsistent data in patients' diaries and medical records. In total, we collected data of 413 patients (115 children and 298 adults) with HA or HB. The median age in the whole cohort was 32 years, in the paediatric group 9 years and in the adult cohort 44 years. Most patients had severe haemophilia (83 children [72.2%] and 203 adults [68.1%]). In total, 96 (83.5%) children and 249 (83.6%) adults suffered from HA. Patients' characteristics are summarized in **Table 1**.

Therapeutic Regimen

Almost all children (98.8%) with severe haemophilia were treated prophylactically. Because of the young age, one infant born in 2015 with severe haemophilia had an on-demand treatment with 500 IU. He started prophylaxis in early 2016. In the adult cohort, 162 (80.2%) PWSHs had a prophylactic treatment in 2015. In patients with moderate haemophilia, more children had a prophylaxis compared with adults (54.5 vs. 18.4%). Five (71.4%) children with moderate HA but only one (25%) child with moderate HB were on prophylaxis. In seven (31.8%) adults with moderate HA but not in adults with moderate HB, a prophylactic factor substitution was prescribed.

Table 1 Characteristics of 413 patients included in the study

			Children	Adults
Age (y)		<i>n</i> ; median (range)	115; 9 (1–17)	298; 43.5 (18–83)
Body weight (kg)		<i>n</i> ; median (range)	115; 30 (8–111)	292; 81.1 (46–130)
BMI (kg/m ²)		<i>n</i> ; median (range)	112; 17.6 (6.7–34)	281; 26 (17.9–42.6)
Haemophilia A	Severe	<i>n</i> , (%)	74 (64.4%)	176 (59.0%)
	Moderate	<i>n</i> , (%)	7 (6.1%)	22 (7.4%)
	Mild	<i>n</i> , (%)	15 (13%)	51 (17.1%)
Haemophilia B	Severe	<i>n</i> , (%)	9 (7.8%)	27 (9.1%)
	Moderate	<i>n</i> , (%)	4 (3.5%)	16 (5.4%)
	Mild	<i>n</i> , (%)	6 (5.2%)	6 (2%)
Therapeutic regimen	Prophylaxis	<i>n</i> , (%)	90 (78.3%)	171 (57.4%)
	On-demand	<i>n</i> , (%)	25 (21.7%)	127 (42.6%)
Inhibitor status	Active inhibitor	<i>n</i> , (%)	2 (1.7%)	3 (1%)
	History of an inhibitor	<i>n</i> , (%)	10 (8.7%)	9 (3%)

Abbreviation: BMI, body mass index.
 Note: The numbers are given for patients with available data.

In 2005 only 90% of the children with severe haemophilia and 64% of the adults were on prophylaxis.⁸ Change in therapeutic regimen is shown in **Fig. 1**.

In total, 67.2% of children with severe HA on prophylaxis were treated with doses ranging from 20 to 39 IU/kg BW FVIII or FIX, while 79.4% of the adults with severe HA on prophylaxis were treated with ≤29 IU/kg BW FVIII or FIX. In addition, more children had a dose ≥40 IU/kg BW compared to adults (HA 11.5 vs. 4.4%; HB 22.2 vs. 0%). Prophylaxis was administered in patients with severe HA three times per week in 51 (83.6%) children but only in 76 (55.9%) adults. Prophylaxis regimens in children and adults are summarized in **Tables 2 and 3**.

In 2015 a total of 48 (42.1%) children and 124 (41.6%) adults were treated with recombinant factor concentrates. In the group of PWSHs, more adults (*n* = 106; 52.5%) than children (*n* = 37; 44.6%) were treated with a recombinant factor. In

contrast, in 2005 only 19% of the children and 24% of the adults were on recombinant factor concentrates (**Fig. 2**).

Factor Consumption

Median annual factor consumption in PWSHs was 125,400 (84,438–202,000) IU in children (*n* = 80) and 183,500 (94,500–279,000) IU in adults (*n* = 196). Children with severe HA had a trend toward higher median factor consumption compared with children with severe HB (129,000 [90,000–209,000] vs. 80,400 [68,700–138,300] IU; *p* = 0.074), reaching significance in adult patients (186,000 [116,750–289,000] vs. 116,400 [43,200–247,000] IU; *p* = 0.047). When factor consumption was adjusted to BW, children with severe HA had a significantly higher consumption than children with severe HB (4,700 [2,902–6,272] vs. 2,062 [1,468–4,075] IU/kg; *p* < 0.01). This difference was also seen in adult patients (2,288 [1,503–3,645] vs. 1,940 [575–2,942] IU/kg; *p* = 0.040). Remarkably, children





Fig. 1 Therapeutic regimen in patients with severe haemophilia: (a) children in 2005; (b) children in 2015; (c) adults in 2005; (d) adults in 2015.

Table 2 Prophylaxis regimens in 70 children with severe haemophilia without inhibitors

Children	Haemophilia A, n = 61				Haemophilia B, n = 9			
	≤19 IU/kg	20–29 IU/kg	30–39 IU/kg	≥40 IU/kg	≤19 IU/kg	20–29 IU/kg	30–39 IU/kg	≥40 IU/kg
1 ×/d	0	0	0	0	0	0	0	0
3 ×/wk	10	18	17	6	0	0	0	0
2 ×/wk	3	3	2	0	0	2	2	1
1 ×/wk	0	0	1	1	0	2	1	1
Total	13 (21.3%)	21 (34.4%)	20 (32.8%)	7 (11.5%)	0 (0.0%)	4 (44.5%)	3 (33.3%)	2 (22.2%)

Table 3 Prophylaxis regimens in 153 adults with severe haemophilia without inhibitors

Adults	Haemophilia A, n = 136				Haemophilia B, n = 17			
	≤19 IU/kg	20–29 IU/kg	30–39 IU/kg	≥40 IU/kg	≤19 IU/kg	20–29 IU/kg	30–39 IU/kg	≥40 IU/kg
1 ×/d	0	0	0	1	1	0	0	0
3 ×/wk	35	26	12	3	2	1	0	0
2 ×/wk	12	25	9	2	4	4	0	0
1 ×/wk	5	5	1	0	2	2	1	0
Total	52 (38.2%)	56 (41.2%)	22 (16.2%)	6 (4.4%)	9 (52.6%)	8 (42.1%)	1 (5.3%)	0 (0.0%)

**Fig. 2** Use of factor concentrates in patients with haemophilia in 2005 and 2015.

with moderate HA had a median annual factor consumption of 144,000 (9,000–195,000) IU while adults with moderate HA used only 34,500 (6,750–161,250) IU ($p = 0.53$). Patients with moderate HA used significantly more factor concentrates than patients with moderate HB (children: 144,000 [9,000–195,000] vs. 7,800 [1,650–41,625] IU, $p < 0.01$; adults: 34,500 [6,750–161,250] vs. 1,200 [0–6,000] IU, $p < 0.01$).

In relation to their BW, children with severe haemophilia used more factor concentrates than adults. Median annual consumption in children with severe HA was 4,700 [2,902–6,272] IU/kg and for adults 2,288 [1,503–3,645] IU/kg ($p < 0.01$). This difference was still significant when patients with on-demand therapy were excluded (4,727 [3,042–6,281] vs. 2,529 [1,741–3,848] IU/kg, $p < 0.01$). In HB patients no statistical significance was observed (2,062 [1,468–4,075] vs. 1,940 [575–2,942] IU/kg, $p = 0.607$).

Compared with 2005, mean factor consumption increased in children with severe HA and HB by around 50,000 IU and

adults by around 65,000 IU. We were not able to conduct adequate and detailed statistical comparison between our results and those for 2005 because we did not have the individual factor consumption for patients in 2005. Mean factor consumption is summarized in **Table 4**.

Bleeding Rates

Children with severe haemophilia on prophylaxis had a mean ABR of 4.2 (median 2, IQR 1–6) and a mean documented AJBR of 1.1 (median 0, IQR 0–1). Adults with severe haemophilia on prophylaxis had a mean ABR of 5.1 (median 3, IQR 1–7) and a mean documented AJBR of 1.9 (median 0, IQR 0–2.8). Major bleeds were rare in adults ($n = 8$, mean 0.05) and there was no documented major bleeding in children with severe haemophilia. However, substitutions for unclear reasons were frequent: in children 100 and in adults 398 substitutions of unknown reason were documented. In PWSHs, children and adults had 82 and 316

Table 4 Mean annual factor consumption in patients with haemophilia in 2005 and 2015

		Children		Adults	
		2015	2005	2015	2005
Haemophilia A	Severe	151,489 <i>n</i> = 71	98,894 <i>n</i> = 81	217,151 <i>n</i> = 169	151,394 <i>n</i> = 246
	Moderate	106,429 <i>n</i> = 7	65,486 <i>n</i> = 29	75,682 <i>n</i> = 22	49,603 <i>n</i> = 96
	Mild	16,200 <i>n</i> = 15	26,524 <i>n</i> = 60	13,804 <i>n</i> = 51	3,631 <i>n</i> = 158
Haemophilia B	Severe	105,200 <i>n</i> = 9	64,256 <i>n</i> = 20	159,185 <i>n</i> = 27	85,295 <i>n</i> = 51
	Moderate	17,025 <i>n</i> = 4	22,967 <i>n</i> = 3	3,520 <i>n</i> = 15	13,900 <i>n</i> = 30
	Mild	167 <i>n</i> = 6	8,500 <i>n</i> = 8	9,200 <i>n</i> = 5	6,393 <i>n</i> = 46

unclear substitutions, respectively. Bleeding rates in PWSHs on prophylaxis are displayed in ▶Table 5.

Mean ABR in adult PWSHs on prophylaxis was 5.1 versus 10.2 in patients with on-demand therapy ($p = 0.19$). Mean AJBR was significantly lower in patients on prophylaxis (1.9 vs. 5.5, $p < 0.01$).

Influence of Body Weight and BMI on Factor Consumption and Bleeding Rates

According to the classification of Kromeyer-Hauschild in 112 children with available data, 85 (75%) had a normal BW, 7 (6.2%) were overweight, 11 (9.7%) underweight and 9 (8.0%) patients were obese. Children with severe haemophilia showed the same distribution (underweight 10%, normal weight 73.3%, overweight 6.3%, obese 10%).

In 281 adult patients with available data, 118 (42.0%) had a normal BW, 96 (34.2%) were overweight, 47 (16.7%) had obesity grade 1 and 15 (5.4%) obesity grade 2 or 3, while only 5 (1.8%) were underweight, showing the same distribution in adults with severe haemophilia.

Overweight and obese children with severe haemophilia without inhibitors on prophylaxis had lower factor consumption per kg BW than children with normal weight or underweight. In adults this difference did not reach statistical significance. In addition, bleeding rates in children and adults with and without overweight were not statistically different (▶Table 6).

Inhibitors

Among the 115 children, only two (1.7%) had an active inhibitor against FVIII, revealed by a positive Bethesda test at the time of the survey. Both had an inhibitor titer > 5 Bethesda units (BU). Another 10 children (8.7%) had a history of an inhibitor but a negative Bethesda test at the time of our survey. The historical titer was > 5 BU in five (50%) children.

Among the 298 adults, three (1.0%) had an active inhibitor (one low titer and two high titers). Another 8 patients had a history of an inhibitor (2 low titer, 3 high titer and 3 with unknown titer).

Virology

All children with available data were negative for HIV, HCV-PCR and HBs-antigen. There was one anti-HCV-positive child and another anti-HBc positive child. Of the 112 children with available laboratory findings or vaccination records, 105 (93.8%) had a detectable anti-HBs titer. Seven adults with haemophilia (2.3%) and six adults with severe haemophilia (3.2%) were carriers of the HBs-antigen. The prevalence of anti-HBc-positive patients was 34.2% in the whole cohort of adult patients and 47.3% in adults with severe haemophilia. In the whole adult population, we found 112 (37.6%) anti-HCV-positive patients, most of them had severe haemophilia ($n = 101$; 53.2%). However, only 13 (6.8%) PWSHs were HCV-PCR positive.

In 2005, 149 patients were documented as being anti-HCV positive. Of these 149 patients, 95 (63.8%) were HCV-PCR

Table 5 Bleeding rates in patients with severe haemophilia on prophylaxis without inhibitor

		Total number of documented bleeds/substitutions, <i>n</i>	Mean	Median	IQR
Children, <i>n</i> = 79	ABR	331	4.2	2	1–6
	AJBR	75	1.1	0	0–1
	Major bleeds	0	0	0	0–0
	Minor bleeds	174	2.2	1	0–3
	Unclear substitutions	82	1.0	0	0–1
Adults, <i>n</i> = 148	ABR	749	5.1	3	1–7
	AJBR	289	1.9	0	0–2.8
	Major bleeds	8	0.05	0	0–0
	Minor bleeds	136	0.92	0	0–1
	Unclear substitutions	316	2.2	0	0–2

Abbreviations: ABR, annualized bleeding rate; AJBR, annualized joint bleeding rate; IQR, interquartile range.

Table 6 Factor consumption and bleeding rates in patients with severe haemophilia without inhibitors on prophylaxis according to body weight and BMI

		Children			Adults		
		≤ Normal weight	≥ Overweight	<i>p</i>	BMI < 30	BMI ≥ 30	<i>p</i>
Annual factor use (IU)	Median (Q25–Q75)	124,800 (88,500–211,000) <i>n</i> = 65	140,750 (103,350–171,625) <i>n</i> = 12	0.844	197,200 (144,000–299,750) <i>n</i> = 122	245,750 (201,250–337,750) <i>n</i> = 28	0.111
Annual factor use/kg BW (IU/kg)	Median (Q25–Q75)	4,755 (3,365–6,123) <i>n</i> = 65	2,242 (2,034–4,384) <i>n</i> = 12	0.045	2,543 (1,730–3,927) <i>n</i> = 122	2,284 (1,721–3,112) <i>n</i> = 28	0.235
Annual factor use/BMI (IU/BMI)	Median (Q25–Q75)	8,102 (5,553–11,572) <i>n</i> = 65	5,703 (4,115–7,193) <i>n</i> = 12	0.074	7,851 (5,745–11,833) <i>n</i> = 121	6,936 (5,762–9,335) <i>n</i> = 28	0.125
ABR	Median (Q25–Q75)	3 (1–6) <i>n</i> = 65	2 (0–4) <i>n</i> = 12	0.269	3 (0.25–7) <i>n</i> = 114	2 (1–3.5) <i>n</i> = 28	0.333
AJBR	Median (Q25–Q75)	0 (0–1) <i>n</i> = 65	0 (0–0) <i>n</i> = 12	0.187	0 (0–3) <i>n</i> = 114	0 (0–1) <i>n</i> = 28	0.199

Abbreviations: ABR, annualized bleeding rate; AJBR, annualized joint bleeding rate; BMI, body mass index; IQR, interquartile range.

positive. In 2015 this rate decreased to 12.9%. Available data about virology are summarized in [Table 7](#).

Discussion

The aim of this retrospective study was to demonstrate changes in haemophilia care in East Germany and to compare the data obtained in 2015 with those from the previous study of the KHDO one decade ago.⁸ We collected data from 413 PWHs from 12 haemophilia treatment centres in 2015 and evaluated them with regard to patients' characteristics, factor consumption, bleeding rates and infectious diseases.

We found a stronger adherence to the prophylactic regimen in 2015 compared with 2005. Almost all children and 80% of the adult PWSHs received prophylactic substitution. As a result, factor consumption increased within the last decade but still remains moderate. Other studies found the annual factor consumption in adults on prophylaxis to be

4,102 IU/kg BW (median) in severe HA⁵ and 4,945 IU/kg BW (mean) in severe HB.¹⁴ In our cohort adults with severe HA and HB on prophylaxis only used 2,288 IU/kg BW (median) and 1,845 IU/kg BW (mean), respectively.

The median annual, BW-related consumption in prophylactically treated children with severe HA was significantly higher compared with adults receiving prophylaxis (4,727 [3,042–6,281] vs. 2,529 [1,741–3,848] IU/kg, *p* < 0.01). Compared with 2005, mean factor consumption in 2015 increased in children with severe HA and HB by approximately 50,000 IU.

This moderate increase in factor consumption can be further explained with a change in treatment strategies in PWHs. As described in the literature and performed in many haemophilia centres, the treatment strategy has changed in the last decade from a regimen based on BW and fixed time intervals to a more personalized prophylactic regimen based on individual factor pharmacokinetics, trough levels and bleeding rates with the

Table 7 Prevalence of viral infections in children and adults with haemophilia

	Children, <i>n</i> (%)	Children with severe haemophilia, <i>n</i> (%)	Adults, <i>n</i> (%)	Adults with severe haemophilia, <i>n</i> (%)
HIV positive	0, (0%) <i>n</i> = 113	0, (0%) <i>n</i> = 81	9, (3%) <i>n</i> = 277	5, (2.7%) <i>n</i> = 188
Anti-HCV positive	1, (0.9%) <i>n</i> = 113	1, (1.2%) <i>n</i> = 81	112, (37.6%) <i>n</i> = 279	101, (53.2%) <i>n</i> = 190
HCV-PCR positive	0, (0%) <i>n</i> = 114	0, (0%) <i>n</i> = 82	14, (4.7%) <i>n</i> = 279	13, (6.8%) <i>n</i> = 190
HBs-Ag positive	0, (0%) <i>n</i> = 112	0, (0%) <i>n</i> = 80	7, (2.3%) <i>n</i> = 275	6, (3.2%) <i>n</i> = 186
Anti-HBc positive	1, (0.9%) <i>n</i> = 112	1, (1.3%) <i>n</i> = 80	102, (34.2%) <i>n</i> = 268	86, (47.3%) <i>n</i> = 182

Abbreviations: HBs-Ag; hepatitis B virus surface antigen; HCV, hepatitis C virus; HCV-PCR, hepatitis C virus-polymerised chain reaction; HIV, human immunodeficiency virus.

aim of zero bleeds for all haemophilia patients.^{15–18} To achieve this aim, higher trough levels were aspired which might have resulted in the increase in factor consumption. The variety of treatment regimens in our patients in 2015 and the low bleeding rate show that personalized prophylaxis results in low bleeding rates with a comparably low factor consumption. However, due to the lack of individual data from 2005, we cannot exclude that other factors like an increase in BW might be the cause for the increased factor consumption, making it difficult to draw final conclusions.

Apart from this, we document a shift from the use of plasma-derived to recombinant factor concentrates. As all plasma-derived factor concentrates currently licensed in Germany are safe in terms of transmission of infections, this change is more likely due to the fact that recombinant factors are easier in handling and storage.¹⁹ In addition, switching patients from plasma-derived to recombinant factor concentrates is not related to inhibitor development in previously treated patients (PTP),^{20–22} which might have encouraged patients and physicians to prefer recombinant factors. Interestingly, the shift to recombinant factors is seen not only in children but also in adults. A recently published study reported a higher incidence of inhibitor development following treatment with recombinant factor concentrates in previously untreated patients (PUPs).²³ It will be interesting to see how these data will influence the factor use especially in children in the future.

The prevalence of obesity in our patients was 8% in children and 10% in adults. Other studies reveal a much higher prevalence in other cohorts.²⁴ As fatty tissue has lower blood volume, PWHs with obesity have an increased in vivo recovery when dosed per BW, resulting in higher trough levels.^{25–27} Our data reveal lower factor consumption in obese children with haemophilia when calculated per BW without an increased bleeding tendency. The same effect is seen in adults without reaching statistical significance. The reason for this finding might be the fact that physicians rather treat patients according to their bleeding tendency and trough levels than with a fixed dose per BW. When interpreting these data, it has to be taken into account that obese patients tend to have less physical activity that might lead to a lower bleeding rate as well. However, another study in adult patients with HA obese patients showed identical bleeding rates and factor consumption per BW compared with non-obese patients.²⁷

Our data show a comparably low inhibitor rate of approximately 10% in children and even lower in adults. The reasons for the low inhibitor rate might be the high amount of patients being treated with plasma-derived factor concentrates which are known to be associated with a lower inhibitor risk in PUPs.²³

Our data regarding infections are very encouraging. No child with haemophilia had an active infection with HCV, HBV or HIV. Already in 2005 no child with haemophilia had an active infection with HCV or HIV. Moreover, in the adult cohort we were able to document a dramatic reduction in the rate of patients with active hepatitis C infection. This is clearly the effect of the progress in treatment options in the last few years.

Limitations

Our study has some limitations due to its retrospective design. Factor substitution and bleeding rates were documented by the patients. As a result real factor consumption and bleeding rates might have been higher in some patients and we cannot exclude a selection bias towards a more compliant patient population represented in this study. In addition, a high number of unclear substitutions and bleedings occurred. These might have been mild bleedings, substitutions for a bleeding aura or intensified prophylaxis for physical activities, but no final assertion can be made. To diminish this effect, only patient diaries with consistent documentation were used and the treating physicians were contacted in case of conspicuities. In addition, we compared collective data from the reports submitted to the Paul Ehrlich Institute in 2005 with individual patients' data from 2015. Therefore, we were unable to analyse changes regarding bleeding rates, treatment regimens and obesity in the last decade. Moreover, we were unable to perform a statistical analysis to compare factor consumption between 2005 and 2015.

Summary and Conclusion

Comparing data from 2005 with 2015, more PWSHs in the eastern part of Germany received a prophylactic factor substitution, resulting in a moderate increase in factor consumption and low bleeding rates. More patients were treated with recombinant factor concentrates in 2015. Between 2005 and 2015, most PWHs with active HCV infections were successfully treated.

Funding

The study was supported by an unrestricted grant from Bayer HealthCare.

Conflict of Interest

Adj. Prof. Dr. J. Koscielny declares the following conflicts of interest: speaker honoraria from Aspen, Bayer Health Care Pharmaceuticals, Daiichi Sankyo, Boehringer Ingelheim, CSL Behring, Sanofi-Aventis, Shire, Roche, Chugai, Pfizer, BMS, Mitsubishi Pharma, Ferring GmbH, Sanofi-Aventis and Novo Nordisk. Adj. Prof. Dr. J. Koscielny is also a medical advisor for CSL Behring International, Bayer HealthCare Pharmaceuticals (national and international), Chugai, Roche, Shire (national) and Novo Nordisk (national) during the last 3 years. Dr. Halm-Heinrich reports personal fees and non-financial support from Novo Nordisk Deutschland, non-financial support from CSL Behring Deutschland, non-financial support from Shire Deutschland GmbH, non-financial support from Bayer Vital GmbH, non-financial support from Biotest AG, non-financial support from LFB GmbH, outside the submitted work. Dr. Klamroth reports grants and personal fees from Bayer, grants and personal fees from CSL Behring, grants and personal fees from Roche, grants and personal fees from Pfizer, grants and personal fees from Biomarin, grants and

personal fees from Takeda/Shire, grants and personal fees from Novo Nordisk, grants and personal fees from SOBI, outside the submitted work. Dr. Schilling reports non-financial support from Bayer Vital GmbH, personal fees from LEO Pharma GmbH, personal fees from Novo Nordisk Pharma GmbH, personal fees from Swedish Orphan Biovitrum GmbH, non-financial support from Roche Pharma AG, outside the submitted work. Prof. Knöfler reports grants and lecture honorarium from Bayer Vital GmbH, Novo Nordisk GmbH, Shire Deutschland GmbH, CSL Behring GmbH, Intersero GmbH, Biotest AG and Swedish Orphan Biovitrum GmbH during the 36 months prior to publication. Dr. Tregel reports other from Grifols, grants from Octapharma, other from Shire, outside the submitted work. Dr. Pfrepper reports and Dr. C. Pfrepper declares the following conflicts of interest: speaker honoraria from BMS, Pfizer, Roche, Shire and CSL Behring. Dr. C. Pfrepper is also a medical advisor for CSL Behring, Bayer HealthCare, Roche, Chugai, Shire, Novo Nordisk and Pfizer during the last 3 years.

References

- Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. *Haemophilia* 2013;19(01):e1–e47
- den Uijl I, Biesma D, Grobbee D, Fischer K. Outcome in moderate haemophilia. *Blood Transfus* 2014;12(Suppl 1):s330–s336
- Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. *N Engl J Med* 2007;357(06):535–544
- Tagliaferri A, Feola G, Molinari AC, et al; POTTER Study Group. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. *Thromb Haemost* 2015;114(01):35–45
- Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. *J Thromb Haemost* 2017;15(11):2115–2124
- Nijdam A, Foppen W, van der Schouw YT, Mauser-Bunschoten EP, Schutgens REG, Fischer K. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. *Haemophilia* 2016;22(06):852–858
- Hesse J. deutsches-haemophileregister-dhr-patientenzahlen. Available at: https://www.pei.de/SharedDocs/Downloads/blut/dhr-deutsches-haemophileregister/deutsches-haemophileregister-dhr-patientenzahlen.pdf?__blob=publicationFile&v=54. Accessed January 16, 2019
- Scholz U, Syrbe G, Koscielny J, Klamroth R; Kompetenznetzwerk Hämorrhagische Diathesen Ost (KHDO). Patienten mit Hämophilie A, B oder von-Willebrand-Syndrom Typ 3. Systematische Erfassung im Osten Deutschlands. *Hamostaseologie* 2008;28(03):150–154
- Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. *J Thromb Haemost* 2014;12(11):1935–1939
- World Health Organization. Obesity and overweight. Available at: <http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Updated February 16, 2018. Accessed November 14, 2018
- Kromeyer-Hauschild K, Wabitsch M, Kunze D, et al. Perzentile für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. *Monatsschr Kinderheilkd* 2001;149(08):807–818
- Moss A, Wabitsch M, Kromeyer-Hauschild K, Reinehr T, Kurth B-M. Prävalenz von Übergewicht und Adipositas bei deutschen Einschulkindern. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2007;50(11):1424–1431
- Olivieri M, Königs C, Heller C, et al. Prevalence of obesity in young patients with severe haemophilia and its potential impact on factor VIII consumption in Germany. *Hamostaseologie* 2019 (e-pub ahead of print). Doi: 10.1055/s-0039-1677874
- Chen CX, Baker JR, Nichol MB. Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. *Value Health* 2017;20(08):1074–1082
- Collins PW. Personalized prophylaxis. *Haemophilia* 2012;18 (Suppl 4):131–135
- Jiménez-Yuste V, Auerswald G, Benson G, et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. *Blood Transfus* 2014;12(03):314–319
- Herbert RD, Broderick CR, Barnes C, Billot L, Zhou A, Latimer J. Optimization of prophylaxis for hemophilia A. *PLoS One* 2018;13 (02):e0192783
- Iorio A, Edginton AN, Blanchette V, et al. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations. *Res Pract Thromb Haemost* 2018;2(03):535–548
- Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. *Patient Prefer Adherence* 2018;12:431–441
- Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. *Transfus Sci* 1998;19(02):139–148
- Bacon CL, Singleton E, Brady B, et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). *Haemophilia* 2011;17(03):407–411
- Santagostino E, Auerswald G, Benson G, et al. Switching treatments in haemophilia: is there a risk of inhibitor development? *Eur J Haematol* 2015;94(04):284–289
- Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. *N Engl J Med* 2016;374(21):2054–2064
- Kahan S, Cuker A, Kushner RF, et al. Prevalence and impact of obesity in people with haemophilia: review of literature and expert discussion around implementing weight management guidelines. *Haemophilia* 2017;23(06):812–820
- Henrard S, Speybroeck N, Hermans C. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. *J Thromb Haemost* 2011;9(09):1784–1790
- Blanchette VS, Shapiro AD, Liesner RJ, et al; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. *J Thromb Haemost* 2008;6(08):1319–1326
- Tuinenburg A, Biere-Rafi S, Peters M, et al. Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. *Haemophilia* 2013;19(05):744–752